In a first report, two patients with IDH2-mutant AML developed resistance to the mutant IDH2 inhibitor enasidenib as a result of the emergence of second-site IDH2 mutations in trans (Q316E, I319M) in the wild-type allele. The gene discussed is IDH2; the disease is acute myeloid leukemia.